Immunotherapy has reshaped the landscape of cancer care, moving beyond the traditional triad of surgery, radiation, and chemotherapy toward treatments that harness the body’s own defenses. The discovery of how to inhibit the mechanisms that prevent the immune system from attacking tumors won the Nobel Prize in Physiology or Medicine in 2018, marking a turning point in oncology. Today, researchers are building on that foundation with increasingly precise tools, from personalized vaccines to artificial intelligence, even as challenges around resistance, side effects, and cost persist.
Personalized Vaccines Target Tumor Mutations
At the center of this evolution are neoantigens—tiny mutations on cancer cells that act like red flags for the immune system. Scientists are designing personalized vaccines that train the body to recognize these flags and mount an attack against the tumor. A Phase 2b trial of Moderna and Merck’s mRNA-4157 vaccine, given in combination with the checkpoint inhibitor pembrolizumab, showed improved recurrence-free survival in melanoma patients in 2023.
That data is now driving momentum into larger studies. But the vaccine is just one piece of a much larger puzzle.
Artificial intelligence has become a key tool in this effort. AI is used to predict which patients will respond to immunotherapy, to analyze the tumor microenvironment, and even to help design those personalized neoantigen vaccines. These approaches allow doctors to target abnormal antigens on the surface of tumor cells while protecting healthy tissue, offering a path toward truly personalized medicine.
Combination Therapies and a Growing Trial Landscape
More than 2,000 immunotherapy trials were active globally as of 2023, testing a wide array of strategies. These include bispecific antibodies and next-generation CAR-T cells aimed at solid tumors.
Oncolytic viruses like T-VEC are also being tested in combinations, often alongside checkpoint inhibitors that take the brakes off immune cells. Combination therapies—checkpoint inhibitors paired with chemotherapy, targeted therapy, or radiation—are a major focus of current research, aiming to improve response rates where single drugs have fallen short. The evolution of immunotherapy extends beyond cancer.
These strategies modify or use the immune system to fight disease, and are also being explored for allergies and autoimmune disorders. Some treatments stimulate the immune system to attack malignant cells, while others suppress immune activity to stop inflammation.
Modern approaches include passive methods like monoclonal antibodies and active methods such as vaccines. Some therapies use cell-based transfers to enhance the body’s natural defenses.
Ongoing Hurdles and Regulatory Support
Despite the progress, significant challenges remain. Overcoming primary and acquired resistance is a central hurdle. Managing immune-related adverse events—side effects that can range from mild to severe—requires careful monitoring.
And the cost of these advanced treatments is a barrier that the field is still grappling with. The FDA has granted breakthrough therapy designation to several investigational immunotherapies, a sign that regulators see the promise.
These designations help accelerate development and review of therapies that show early potential. Because responses vary based on genetics and disease type, these therapies offer a path toward more personalized medicine. This shift changes how doctors manage long-term survival and recovery.
For patients who do not respond to standard care, the growing array of options provides new hope. Consult your doctor for medical advice.
